CD274 and head and neck squamous cell carcinoma: Subsequently, its indications have extended to recurrent head and neck squamous cell carcinoma [324], advanced or metastatic NSCLC with PD-L1 positivity [325], metastatic urothelial carcinoma [326], cervical cancer [327], classical Hodgkin lymphoma [328], microsatellite-unstable or mismatch repair-deficient cancer [329], gastric cancer [330] and primary mediastinal large B-cell lymphoma [331], among others.